Application of reagent for inhibiting or knocking out COMP gene and medicine for treating oral submucosal fibrosis
By inhibiting or knocking out the COMP gene, shRNA and CRISPR/Cas9 technology are used to reduce COMP expression, and the problem of abnormal collagen deposition in oral submucosal fibrous disease is solved, achieving significant efficacy and safety in alleviating OSF symptoms.
Patent Information
- Application Number
- CN202410928039.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective treatment methods to inhibit or reverse the abnormal deposition of collagen in oral submucosal fibrosis (OSF), resulting in serious symptoms such as restricted mouth opening, and surgical treatment has problems of heavy trauma and uncertain efficacy.
By developing reagents that inhibit or knock out the COMP gene, shRNA and CRISPR/Cas9 technology reduce COMP gene expression, thereby reducing the expression of type I collagen and XIV collagen, thereby treating OSF.
It significantly reduces the abnormal deposition of collagen, relieves the symptoms of OSF, has significant efficacy and fewer toxic side effects, and provides a safe treatment plan.
Smart Images

Figure CN118924782A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to the application of reagents for inhibiting or knocking out COMP genes and drugs for treating oral submucous fibrosis. Background Art
[0002] Oral submucous fibrosis (OSF) is a chronic, latent oral mucosal disease caused by long-term chewing of betel nut. OSF is a recognized precancerous lesion. At different stages of the disease, the malignant transformation rate of untreated OSF is 4.2%. One of the most important pathological features of OSF is the accumulation of collagen and hyaline degeneration in the lamina propria and submucosa of the oral mucosa caused by the imbalance of synthesis and degradation of the extracellular matrix with type I collagen as the main component. The resulting toughening and pale changes in the oral mucosa, and even more severe, the formation of fibrous cords and the gradual increase in mouth opening limitation are one of the most important clinical symptoms of OSF. Submucosal injection of glucocorticoids or salvia miltiorrhiza solution can partially reverse the clinical symptoms of early and middle stage patients, but it can only play a relieving role; for patients with severe difficulty in opening the mouth, surgery can improve the mouth opening to a certain extent, but the surgical trauma is large, the recovery is difficult after surgery, and the efficacy of scar formation may be uncertain, so surgical treatment of OSF is rarely used in clinical practice.
[0003] Cartilage oligomeric matrix protein (COMP) is a pentameric multidomain protein. Each monomer consists of an N-terminal domain, four type 2 epidermal growth factor-like repeat sequences, seven type 3 calcium-binding repeat sequences and a C-terminal domain.
[0004] In the early stage of the present invention, COMP was screened out through RNA high-throughput sequencing as an important pathogenic factor mediating abnormal collagen deposition. COMP and type I collagen were upregulated in the buccal mucosa of OSF patients, and type XIV collagen was screened out as the partner collagen of type I collagen, which was also upregulated with the development of OSF. Functional experiments showed that the expression of COMP, type I collagen, and XIV collagen were all upregulated in wild-type mice and oral buccal mucosal fibroblasts under the stimulation of arecoline. These results suggest that COMP promotes the progression of OSF by promoting the abnormal deposition of type I collagen with XIV collagen. Targeting COMP can inhibit fibroblast activation and tissue fibrosis, and inhibiting COMP is a potential target for the treatment of oral submucous fibrosis. Therefore, researching and developing substances that inhibit the expression of COMP has a good prospect for the development of drugs for the treatment of oral submucous fibrosis. Summary of the invention
[0005] The pathogenesis of OSF is complex and there is currently a lack of effective therapeutic drugs. The primary purpose of the present invention is to provide an agent for inhibiting or knocking out the COMP gene for use in the preparation of a preparation for treating oral submucous fibrosis. The expression of the COMP gene can be reduced or completely inhibited, thereby alleviating or even reversing the abnormal deposition of collagen, effectively treating OSF.
[0006] Furthermore, the reagent for inhibiting COMP gene includes: shRNA.
[0007] The reagent for knocking out the COMP gene includes a reagent that uses crisper cas9 technology to reduce the expression of the COMP gene at the mRNA level.
[0008] The second object of the present invention is to provide a drug for treating oral submucous fibrosis, which is the reagent for inhibiting or knocking out the COMP gene.
[0009] The medicine also includes a pharmaceutically acceptable carrier or excipient.
[0010] In the treatment of OSF, the drug of the present invention can be used alone or in combination with other drugs.
[0011] The third object of the present invention is to provide the use of an agent for inhibiting or knocking out COMP gene in the preparation of a preparation for reducing type I collagen deposition.
[0012] The reagent for inhibiting COMP gene includes: shRNA.
[0013] The reagent for knocking out the COMP gene includes a reagent that uses crisper cas9 technology to reduce the expression of the COMP gene at the mRNA level.
[0014] The fourth object of the present invention is to provide the use of a reagent for detecting COMP gene in the preparation of a preparation for detecting oral submucous fibrosis.
[0015] The reagent for detecting COMP gene includes PCR detection reagent.
[0016] The OSF described in the present invention refers to fibrosis of the oral mucosa of humans or animals. The symptoms of OSF include: pale changes in the mucosa caused by abnormal collagen deposition in the oral mucosa, scar-like changes and limited mouth opening. The cause of OSF is: long-term chewing of betel nut. The drug described is the main chemical substance in betel nut, namely arecoline.
[0017] The extent of treating OSF described in the present invention is to either cure OSF and normalize it, or to slow down the progression of oral submucous fibrosis.
[0018] Beneficial technical effects of the present invention: The present invention provides shRNA that can specifically inhibit COMP expression, and the shRNA can target and reduce COMP expression, and also provides a crisper cas9 gene editing scheme for knocking out the COMP gene, further reducing the expression of type I collagen and type XIV collagen, thereby being applied to the preparation of anti-OSF drugs. The drug prepared using the above shRNA has the advantages of significant efficacy, low toxicity and side effects, and safe use in the treatment of OSF diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 : Strategies for constructing Comp knockout mouse models through CRISPR / cas-mediated genome engineering.
[0020] Figure 2 : Agarose gel electrophoresis analysis of mouse genotypes.
[0021] Figure 3 :(a) Expression of COMP protein in the positive reference (mouse cartilage); (b) Expression of COMP protein in mouse buccal mucosa.
[0022] Figure 4 :(a)Comp - / - Gross appearance of Comp mice and WT mice; (b) - / - Growth curves of mice and WT mice.
[0023] Figure 5 :WT and Comp - / - HE staining of the buccal mucosa of knockout mice (scale bar = 50 um).
[0024] Figure 6 :(a) Flow chart of animal experiments using OSF animal model to verify the anti-fibrotic effect of knocking out Comp;(b) HE staining of buccal mucosal tissue of mice treated with PBS buffer and arecoline, modified Masson trichrome staining, immunofluorescence staining of type I collagen, and immunofluorescence staining of Comp (scale bar = 50um);
[0025] (c) Statistical analysis of total collagen content; (d) Statistical analysis of type I collagen content; (e) Statistical analysis of Comp content; the results are expressed as mean±SD; n=24; ***p<0.01, ****p<0.0001.
[0027] Figure 7 :Immunoblotting and statistical analysis of COMP in COMP-RNAi fibroblasts treated with arecoline. Data are presented as mean±SD, *p<0.05.
[0028] Figure 8:Immunoblotting and statistical analysis of type Ⅰ collagen in COMP-RNAi fibroblasts treated with arecoline. Data are expressed as mean±SD, *p<0.05. DETAILED DESCRIPTION
[0029] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] The reagents and raw materials used in the present invention are commercially available.
[0031] The experimental results were expressed as mean ± standard error, and the independent sample T test was used for comparison between two groups, and the oneway ANOVA test was used for comparison between multiple groups.
[0032] Example 1 Construction of Comp - / - Mouse
[0033] 1. Gene modification based on fertilized egg injection: The Comp gene (NCBI reference sequence: NM_016685; gene number: ENSMUSG00000031849) is located on mouse chromosome 8. 19 exons have been identified for the COMP gene, of which the ATG start codon is in exon 1 and the TAG stop codon is in exon 19 (transcript: ENSMUST00000003659). Exons 2-9 will be selected as target sequences. sgRNA was constructed 20 bp outside exon 2, and the shearing region was a DNA fragment of about 2891 bp between exon 2 and exon 9 (see Figure 1 ).
[0034] 2. Inject Cas9 and gRNA into fertilized eggs: Select healthy female mice aged 6-7 weeks and perform hormone-induced superovulation. Put them in cages with male mice at a male-to-female ratio of 1:1. After vaginal plug insertion, kill them to obtain fertilized eggs. Microinject Cas9 and gRNA into fertilized eggs together.
[0035] 3. Transplant the fertilized eggs into the body of pseudo-pregnant mother mice: generally 10-15 embryos are transplanted into each fallopian tube, and a total of 20-30 embryos are preferably transplanted.
[0036] 4. The born mice will be raised and bred.
[0037] Example 2: Feeding and breeding of Comp- / - mice
[0038] 1. Mouse breeding environment: All experimental mice were kept in an animal room with specific pathogen free (SPF) level conditions of the Animal Experiment Department of Central South University. The temperature in the barrier environment was stable at 20-26℃, the relative humidity was about 50% to 60%, and the light-dark alternation time was 12h.
[0039] / 12h, noise ≤60dB. During the mouse breeding process, feed, drinking water, cages, and bedding are all sterilized by high temperature and high pressure (121℃, 30min) vacuum sterilization before use. Each time, about 3-4 days of feed are given, and free eating and drinking are implemented. The bedding in the mouse cage is changed twice a week. The number of animals in each cage of all experimental animals does not exceed 5. Each animal is marked by toe clipping. Each cage of animals must be hung with an experimental record card, which records in detail the animal's species, strain, date of birth, cage date, spouse code, production date and other information. The operation and breeding of all experimental animals comply with the National Regulations on the Management and Breeding of Laboratory Animals.
[0040] 2. The ratio of male to female mice is 1:2. The mice are bred together in cages and fed with sterilized sunflower seeds to enhance nutrition. The sexual maturity of mice is 6-8 weeks, the gestation period is about 21 days, and the female mice of childbearing age give birth to 7-10 pups per litter. The survival rate of pups is acceptable. The mother mouse should be stimulated as much as possible 3-4 days after giving birth, otherwise it will have a stress reaction of eating the pups. The mice can be separated and weaned three weeks after birth. The separated mice of childbearing age can be re-caged to obtain more offspring mice as soon as possible.
[0041] 3.Comp - / - Genotyping of mouse offspring
[0042] 3.1 Genome extraction of offspring mice
[0043] (1) Tissue acquisition: When the offspring mice are 2-3 weeks old, ophthalmic scissors are used to cut the tail tip tissue of the mouse, about 1-2 mm in length, and then put it into a 1.5 ml EP tube and quickly bring it back to the laboratory under low temperature conditions. During the sampling process, it is important to use 75% ethanol to clean the instruments after handling the previous animal to avoid cross contamination and incorrect identification results.
[0044] (2) Use the Bimake Mouse Tail Direct PCR Kit (Rapid Genotyping) to extract genes from offspring mice: ① Prepare tissue digestion solution according to the number of mice. The reagent ratio is as follows: single sample Buffer L (100μL) + Protease Plus (2μL). The tissue digestion solution should be prepared immediately and mixed thoroughly before use. ② Add 100μL of fresh tissue digestion solution to each EP tube containing mouse tail tissue sample and digest in a 55℃ water bath for 15 minutes. When digesting the tissue, be sure to completely immerse the tissue in the digestion solution. ③ Place the sample in a 95℃ metal bath and incubate for 5 minutes to inactivate the protease in the digestion solution. Centrifuge at 12000rpm for 5 minutes and take the supernatant as a PCR template. The digested supernatant can be stored at -20℃ for a long time for future use.
[0045] 3.2 PCR amplification
[0046] (1) Primer design and synthesis
[0047] The PCR primer sequences are shown in Table 1:
[0048] Table 1. Primer sequence list
[0049]
[0050] (2) PCR reaction: ① In order to ensure the efficiency and specificity of PCR amplification, 20uL of the reaction system was prepared on ice. The system composition is shown in Table 2; ② Amplification was performed using a PCR instrument. The reaction conditions were shown in Table 3
[0051] Table 2. PCR amplification reaction system
[0052]
[0053] Table 3. PCR reaction program
[0054]
[0055] 3.3 Determination of genotype by agarose electrophoresis:
[0056] (1) Preparation of agarose gel: Prepare agarose gel of the required size according to the number of samples. Heat 2% agarose powder + 1×TAE buffer in a microwave oven for 2 minutes. Shake well and continue heating for 1 minute to avoid over-boiling. After cooling slightly, add 1×Gelred nucleic acid dye and shake gently to mix the dye thoroughly and avoid bubbles. Pour the mixture into a pre-assembled mold and cool it into shape before electrophoresis.
[0057] (2) Place the agarose gel in an electrophoresis tank filled with 1×TAE buffer. The buffer should cover the agarose gel. Add 4uL DNA Marker to the first well in each row and add 4μl of the final product of the PCR reaction to the subsequent wells. The electrophoresis voltage is 200V and the time is 20 minutes.
[0058] (3) Interpretation of electrophoresis results: Analyze the agarose gel after electrophoresis using a gel imaging analyzer. The primer design strategy is shown in the figure (see Figure 1 ), the PCR reaction product of WT mice involving F1+R1 primers is a 3567bp band, which is beyond the range of this reaction system, so no positive band was observed in electrophoresis, and a 300bp band was observed in homozygous and heterozygous mice. The F2 sequence is located in the gene knockout region, so the PCR reaction involving the gene-edited DNA fragment F2+R1 primers is negative, and the PCR reaction product of heterozygous and WT mice F2+R1 is positive, that is, a 319bp band can be seen in electrophoresis. Combining the electrophoresis results of the PCR reaction products of the two sets of primers, only the 300bp band can be seen, which is identified as the Comp knockout homozygous, the 319bp and 300bp bands can be seen, which is identified as the Comp knockout heterozygous, and only the 319bp band can be identified as the WT mouse (see Figure 2 ).
[0059] 3.4 Verification of COMP knockout efficiency
[0060] (1) COMP is highly expressed in cartilage tissue, and WT mice and Comp - / - The rib cartilage was obtained after euthanasia; the rib cartilage tissue was ground in a cryogenic grinder using RIPA lysis buffer containing protease inhibitors and grinding beads, and intermittently sonicated on ice, centrifuged at 12000rpm for 10 minutes at 4°C, and the supernatant was aspirated. 5×SDS gel loading buffer was added in proportion, and denatured at 95°C for 10 minutes. Conventional WB loading electrophoresis, transfer, and blocking were performed, the primary antibody was incubated at 4°C overnight, the membrane was washed with PBST for 10 minutes 3 times, the corresponding secondary antibody was incubated at room temperature for 1 hour, and the membrane was washed with PBST for 10 minutes 3 times again before chemiluminescence. The results showed that COMP was expressed in the rib cartilage tissue of WT mice, while Comp - / - COMP expression is not observed in mice (see Figure 3 a);
[0061] (2) After euthanasia, the buccal mucosa of WT mice and Comp- / - mice was collected; fixed with 4% paraformaldehyde, routinely dehydrated and embedded in transparent wax after 24 hours, 4um slices were sliced, baked at 60℃ for 2 hours, routinely dewaxed to water, microwave-high temperature repaired with sodium citrate antigen repair solution, blocked with goat serum for 30 minutes, incubated with primary antibody at 4℃ overnight, washed three times with PBS, 5 minutes each time; incubated with corresponding immunofluorescence secondary antibody at room temperature for 1 hour, washed three times with PBS, and sealed with anti-fluorescence quenching sealing agent containing DAPI; images were obtained using a fluorescence microscope. The results showed that COMP fluorescence signal was seen in the buccal mucosa of WT mice, and Comp - / - COMP expression was not observed in the mouse buccal mucosa (see Figure 3 b).
[0062] The above results verify that Comp - / - Knockout efficiency in mice.
[0063] Example 3Comp - / - Mouse phenotype observation
[0064] 1. The left buccal mucosa of Comp- / - mice and WT mice that had been genetically identified was immediately obtained after euthanasia; it was then fixed in 4% paraformaldehyde solution, fixed at 4°C for 24 hours, and then routinely dehydrated, transparently embedded and sectioned; in preparation for subsequent Masson trichrome staining and immunofluorescence experiments.
[0065] 2. Hematoxylin-eosin tissue staining, also known as HE staining, is the most commonly used common staining method in clinical and scientific research.
[0066] 3. The results showed that Comp gene knockout mice showed normal growth and development ( Figure 4 In histological observation, the buccal mucosal tissue structure of COMP knockout mice showed no obvious abnormalities ( Figure 5 ).
[0067] Example 4 Preparation of OSF Animal Model
[0068] 1. Main reagents and experimental animals
[0069] Arecoline used in the experiment was purchased from MCE, with the catalog number HY-b0489. Isoflurane was purchased from Reward
[0070] 2. Verify the anti-fibrotic effect of Comp knockout using OSF animal model
[0071] The commercialized arecoline powder was diluted with PBS solution to a 4 mg / mL dilution, filtered and stored in a -80°C deep freezer for later use. The experimental group mice were anesthetized with isoflurane anesthetic, and then injected with the arecoline dilution in the left cheek with a 30G insulin syringe. The dosage was 20 mg / Kg, and the frequency was once a day. The mice in the control group were replaced with an equal volume of PBS buffer solution, and the administration method was the same as the experimental group. After 12 consecutive weeks of injection, the mice were euthanized.
[0072] The left buccal mucosa of all experimental mice was obtained immediately after euthanasia; fixed with 4% paraformaldehyde, and the sampling site avoided the needle insertion point at the corner of the mouth to avoid obtaining scar tissue. After fixation for 24 hours, the sections were routinely dehydrated and transparently embedded for subsequent Masson trichrome staining and immunofluorescence experiments.
[0073] Masson's trichrome staining is a classic method for specific staining of collagen fibers. After Masson's staining, muscle fibers appear red and collagen fibers appear blue.
[0074] Immunofluorescence technology is beneficial for the localization and semi-quantification of antigenic substances in tissues or cells through antigen-antibody reaction.
[0075] 3. The results showed that compared with the control group, collagen deposition and thickening of the lamina propria were observed under the buccal mucosa of wild-type mice (Arec.), and this difference was statistically significant (P < 0.001). - / - There was no significant difference between the experimental group and the control group of mice (P>0.05). Immunofluorescence results showed that the expression of type I collagen in the WT mouse arecoline group was upregulated compared with the control group, while there was no significant difference in the expression of type I collagen in COMP knockout mice. In terms of COMP expression, the expression of WT arecoline group was upregulated compared with the control group, while COMP expression was not observed in COMP knockout mice (see Figure 6 ).
[0076] Example 5 Construction of shRNA Lentivirus
[0077] 1. Preparation of shRNA lentiviral clones: linearized vectors are obtained by restriction endonuclease digestion. Primers are annealed to prepare target fragments. The designed primers add restriction sites at both ends. After annealing, the primers contain the same restriction sites at both ends of the linearized cloning vector. A reaction system is prepared with the linearized vector and the annealed product, and a ligation reaction is performed, and the product is directly transformed. Single clones on the plate are picked for PCR identification, and positive clones are sequenced and analyzed. The correct cloned bacterial solution is expanded and extracted to obtain a high-purity plasmid for downstream virus packaging.
[0078] shRNA design:
[0079]
[0080] Target lentiviral vector
[0081] Vector name: GV112
[0082] Component sequence: hU6-MCS-CMV-Puromycin
[0083] Control insert sequence: TTCTCCGAACGTGTCACGT
[0084] 2. Plasmid Transfection and Lentivirus Harvest
[0085] 2.1 48 h before transfection, HEK293T cells in logarithmic growth phase were digested with trypsin and the cell density was adjusted to about 5 x 10 in medium containing 10% serum. 6 cells / 15mL, re-seeded in 10 cm cell culture dishes, 37°C, 5% CO 2 Culture in an incubator. When the cell density reaches 70% to 80% after 48 hours, it can be used for transfection;
[0086] 2.2 1 h before transfection, replace the culture medium with 2% serum;
[0087] 2.3 Add the prepared DNA solutions (20 μg of GV112 vector plasmid (including shRNA), 15 μg of pHelper 1.0 vector plasmid, 10 μg of pHelper 2.0 vector plasmid) (vectors purchased from GeneCare Gene) to a sterile centrifuge tube, mix evenly with the corresponding volume of GeneCare transfection reagent, adjust the total volume of the transfection system to 1 mL, and incubate at room temperature for 15 min;
[0088] 2.4 Slowly add the transfection system to the culture medium of HEK293T cells, mix well, and incubate at 37°C with 5% CO 2 Culture in a cell culture incubator. Note: The transfection system must be added dropwise evenly and try not to blow the cells up.
[0089] 2.5 After 6-8 hours of culture, discard the culture medium containing the transfection system mixture, add 10 mL of PBS solution to wash once, gently shake the culture dish to wash the remaining transfection mixture and then discard;
[0090] 2.6 Slowly add 12 mL of cell culture medium containing 2% serum and incubate at 37°C with 5% CO 2 Culture in the incubator for 48 hours.
[0091] 3. Lentivirus Concentration and Purification
[0092] 3.1 According to the cell status, collect the supernatant of HEK293T cells 48h after transfection (transfection can be counted from 0h);
[0093] 3.2 Centrifuge at 4000g for 10 min at 4°C to remove cell debris and impurities;
[0094] 3.3 Filter the supernatant with a 0.45 μm filter into a 40 mL ultracentrifuge tube;
[0095] 3.4 Balance the samples separately, place the ultracentrifuge tubes with virus supernatant one by one into the Beckman ultracentrifuge, set the centrifugation parameters to 25000rpm, the centrifugation time to 2h, and the centrifugation temperature to 4℃; after centrifugation, discard the supernatant, try to remove the liquid remaining on the tube wall, add the corresponding volume of virus preservation solution (PBS or cell culture medium can be used as a substitute), and gently blow and repeatedly to resuspend the precipitate; Note: There will be a certain degree of loss in virus recovery in this step, so try to avoid exposing the virus to room temperature for a long time.
[0096] 3.5 After being fully dissolved, centrifuge at high speed at 10,000 rpm for 5 minutes, take the supernatant and package it as required; prepare samples for testing.
[0097] 4. Lentivirus quality testing
[0098] The key points of lentivirus quality control include physical status testing, safety testing and virus titer testing.
[0099]
[0100] Example 6 Detection of COMP-RNAi Inhibition of COMP Protein Expression by WB
[0101] The specific steps are as follows:
[0102] 1. Plate primary human buccal mucosal fibroblasts in a 60 mm cell culture dish;
[0103] 2. After the cells adhered, COMP-RNAi virus (i.e., shRNA lentivirus constructed in Example 5) was used to infect fibroblasts (MOI=10), and negative viral vector was used as a control to screen infected fibroblasts with puromycin (2 μg / mL);
[0104] 3. Stimulate COMP knockdown fibroblasts and control fibroblasts with arecoline (10ug / ml);
[0105] 4. After 24 hours, wash twice with pre-cooled PBS, add 70ul RIPA lysis buffer, lyse on ice for 20min, collect into 1.5ml centrifuge tube, centrifuge at 12000rpm at 4℃ for 15min, collect supernatant; add 5x loading buffer at 1:4 volume, and boil at 95℃ for 10min;
[0106] 5. Routine WB loading, electrophoresis, transfer and blocking, primary antibody at 4°C overnight, wash the membrane with PBST for 10 minutes 3 times, incubate with corresponding secondary antibody at room temperature for 1 hour, wash the membrane again with PBST for 10 minutes 3 times and then chemiluminescence.
[0107] 6. The results show that COMP expression in control fibroblasts was upregulated under the stimulation of arecoline, while COMP-RNAi infected fibroblasts significantly downregulated COMP compared with control cells ( Figure 7 ).
[0108] Example 7 WB detection of COMP-RNAi inhibition of abnormal deposition of type I collagen
[0109] The cell culture process and WB experimental process are the same as in Example 6;
[0110] The results showed that under the stimulation of arecoline, the ability of control fibroblasts to secrete type Ⅰ collagen was significantly enhanced, while the ability of fibroblasts to secrete type Ⅰ collagen was significantly weakened after knocking down COMP ( Figure 8 ).
[0111] In this experiment, the results of pathological examination, animal experiments and in vitro cell experiments showed that knocking down COMP can significantly inhibit OSF caused by arecoline; after knocking out COMP, mice grew normally, and there was no obvious abnormality in the buccal mucosal tissue structure, but the total collagen and type I collagen content of the buccal mucosal tissue of OSF mice were significantly reduced. Knocking down COMP in fibroblasts can significantly reduce their ability to secrete type I collagen, thereby alleviating the abnormal deposition of type I collagen. The above experimental results prove that knocking down COMP has excellent therapeutic prospects in OSF.
[0112] The results of the above examples show that knocking out or inhibiting COMP has a significant effect on preventing OSF disease, and the gene shRNA that inhibits COMP can be used as an active ingredient to prepare anti-OSF drugs.
[0113] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. Application of reagents that inhibit or knock out the COMP gene in the preparation of preparations for the treatment of oral submucous fibrosis.
2. The use according to claim 1, characterized in that: The reagent for inhibiting COMP gene includes: shRNA.
3. The use according to claim 1, characterized in that: The reagent for knocking out the COMP gene includes a reagent that uses crisper cas9 technology to reduce the expression of the COMP gene at the mRNA level.
4. A drug for treating oral submucous fibrosis, which is the reagent for inhibiting or knocking out the COMP gene as described in any one of claims 1 to 3.
5. Use of reagents that inhibit or knock out the COMP gene in the preparation of preparations for reducing type I collagen deposition.
6. The use according to claim 5, characterized in that: The reagent for inhibiting COMP gene includes: shRNA.
7. The use according to claim 5, characterized in that: The reagent for knocking out the COMP gene includes a reagent that uses crisper cas9 technology to reduce the expression of the COMP gene at the mRNA level.
8. Application of reagents for detecting COMP gene in the preparation of oral submucous fibrosis detection preparations.
9. The use according to claim 8, characterized in that: The reagent for detecting COMP gene includes PCR detection reagent.
Citation Information
Patent Citations
Application of cartilage oligomeric matrix protein in preparing medicine for treating vascular-calcification
CN101670097A
Anti-alpha-v integrin antibody for the treatment of fibrosis and / or fibrotic disorders
WO2017088974A2
